Melbourne, Australia, 16 December 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead […]
The Cartherics team recently gathered at the RACV Club in Healesville for a dynamic and inspiring offsite event focused on collaboration, growth, and celebrating our shared mission.
The theme of the offsite, Stronger Together, set a positive and inclusive tone that resonated throughout the event, encouraging everyone to embrace teamwork, challenges and shared success as we […]
Melbourne, Australia, 8 December 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and […]
Melbourne, Australia, 28 November 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian […]
Cartherics is pleased to announce that it will be presenting at the 8th Australian and New Zealand Society for Extracellular Vesicles (ANZSEV) 2025 Conference in Wellington, New Zealand. ANZSEV 2025 will showcase advances in the field across EVs and biological nanoparticles – their role in cell biology, advances in technologies for their purification and […]
Today, Cartherics proudly hosted a Frocktober Afternoon Tea in support of ovarian cancer awareness and research. Frocktober is a meaningful initiative that encourages us to go the extra style mile – turning heads, starting conversations, and raising vital funds for ovarian cancer research.
We were honoured to welcome Robin Penty, CEO of the Ovarian Cancer Research […]
Cartherics’ COO, Dr Ian Nisbet recently joined Xtalks’ Life Science Podcast to discuss Cartherics’ vision for next generation cell therapies.
He discussed how Cartherics’ platform is building an effectively unlimited supply of CAR NK cells and exploring treatments for underserved conditions like cancer and endometriosis. Dr Nisbet also reflects on his biotech leadership […]
Cartherics is proud to share that our CEO, Professor Alan Trounson, was recently interviewed on 10 News+ by journalists Amelia Brace and Denham Hitchcock.
In the interview, Prof. Trounson provided an in-depth look at Cartherics’ world-first immunotherapies and how this innovative science is shaping the future of treatment for some of the most difficult-to-treat diseases.
Our lead […]
Cartherics is pleased to announce that Mathew Tiedemann has officially completed his PhD, a major milestone in an already impressive scientific journey! His thesis titled, ‘Developing a Clinically Translatable iPSC-derived Immunotherapy’ focused on designing clinically relevant methods to create billions of gene-edited blood cells from stem cells to better detect and destroy ovarian cancer.
Mat’s key […]
In the competitive biotech landscape, groundbreaking science alone isn’t enough. As highlighted in a recent article by Dynamic Business, Cartherics’ strategic appointment of U.S. biotech executive Laurence Nore underscores the critical importance of navigating the complexity of healthcare markets. Laurence emphasises that many promising biotech firms falter not due to flawed science but because they […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
